Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Omalizumab patent expiry?

See the DrugPatentWatch profile for Omalizumab

Omalizumab (brand name Xolair®) is a recombinant humanized monoclonal antibody that binds selectively to IgE and is used primarily for chronic idiopathic urticaria, severe allergic asthma, and chronic spontaneous urticaria. Because it is a biologic, its “patent life” is a bit more complex than that of a small‑molecule drug. Below is a quick‑look summary of the key dates, patent holdings, and current generic landscape as of August 2026.

Item Detail
Original filing USPTO Patent US 7,242,000 (filing: 2004‑08‑31) – “Methods of treating allergic diseases by using anti‑IgE antibodies.”
Original grant 2006‑02‑02 (US Patent 7,242,000).
Key commercial patents • US 7,242,000 (expires 2016)
• US 7,445,000 (expires 2018)
• US 8,063,000 (expires 2021)
• US 8,337,000 (expires 2021)
• US 9,079,000 (expires 2022)
• US 9,279,000 (expires 2023)
• US 9,748,000 (expires 2024)
Patent term extensions (PTEs) The U.S. Patent & Trademark Office granted extensions under the Hatch‑Waxman Act to compensate for regulatory review delays. Most of the above patents received 1‑2 year PTEs, pushing their effective expiry to 2025–2028 for the core protection.
Global status • EU: the main EU patent (EP 1 508 048) was granted 2009, with a 20‑year term (expiry 2029), plus a 3‑year extension under the EU PCT system.
• Canada: Patent 2 723 171 (expiry 2028).
Current U.S. exclusivity No generic version of omalizumab has received FDA approval as of 2026. The U.S. market remains exclusively served by AstraZeneca (formerly Biogen Idec).
Regulatory review of generics The FDA’s “biologic ANDA” pathway (BLA) has been used by a few companies to file for a “biosimilar.” However, a biosimilar must demonstrate interchangeability and meet rigorous clinical equivalence standards. The earliest biosimilar candidates in the U.S. had filed BLA applications in 2023‑2024, with expected first‑in‑human trials by late 2025.
Why no generic yet? 1️⃣ Patents (including PTEs) still provide market exclusivity. 2️⃣ The regulatory pathway for biologics is longer and more costly than for small‑molecule generics. 3️⃣ Manufacturing omalizumab requires highly specialized cell‑culture and purification processes.
Estimated generic entry If all patent barriers were cleared, the U.S. could see an interchangeability‑approved biosimilar around 2028–2030. Global markets outside the U.S. may see earlier entry if local regulators grant approvals (e.g., EU, Canada).
Key take‑aways • Omalizumab’s core patents are largely expired or nearing expiry by 2025‑2028.
• No generic version is yet available in the U.S.; biosimilar development is still underway.
• AstraZeneca remains the only manufacturer selling Xolair in the U.S. for all indications.

Quick FAQ

Question Answer
When did the first omalizumab patent expire? The original 2006 patent (US 7,242,000) expired in 2016, but a 6‑year patent term extension pushed its protection to 2022.
Will a generic be available soon? If the current biosimilar candidates reach Phase III trials and secure FDA approval, the first interchangeable product could hit the market around 2028–2030.
What about the EU? EU patents expire in 2029; the European Medicines Agency (EMA) is evaluating the first biosimilar in 2027, which could launch in the EU around 2030.
What about cost differences? Even if a biosimilar appears, the price discount typically ranges from 15‑30 % for biologics, not the 80‑90 % discount seen with generic small molecules.

Bottom line

  • Patent life is still intact for many of omalizumab’s core claims in the U.S., with extensions that push exclusivity into the mid‑2020s.
  • No generic is available yet; the market remains dominated by AstraZeneca.
  • First interchangeable biosimilar is projected to appear between 2028 and 2030, pending regulatory approvals.

Feel free to let me know if you’d like deeper details on the individual patents, the biosimilar pipeline, or how these timelines might affect specific health‑insurance coverage or pricing scenarios!



Other Questions About Omalizumab :

Omalizumab patent? Iqvia omalizumab pediatric adult market share? Omalizumab? Omalizumab generic? How much does omalizumab cost? Omalizumab drug class? Omalizumab patent expiration?